上海海利生物技术股份有限公司

控股子公司杨凌金海生物技术有限公司与

礼蓝（上海）动物保健有限公司

签订《独家推广协议》

2019年8月20日，海利生物（股票代码：603718.SH）控股子公司杨凌金海生物技术有限公司（以下简称“杨凌金海”）与Elanco US Inc.的子公司礼蓝（上海）动物保健有限公司（以下简称“礼蓝动保”）签订《独家推广协议》。杨凌金海委托礼蓝动保在中国（含香港特别行政区和澳门特别行政区）的市场化营销渠道独家推广杨凌金海的口蹄疫疫苗产品，礼蓝动保将充分发挥其资源和优势协助杨凌金海产品市场推广。

本次杨凌金海与礼蓝动保《独家推广协议》的签订是海利生物国际化合作的重要举措，杨凌金海是经国家农业部批准，由海利生物与阿根廷BiogénesisBagóS.A.公司共同合资兴建、国内唯一的一家中外合资的口蹄疫疫苗生产企业。2019年1月22日，杨凌金海获得猪口蹄疫O型、A型二价灭活疫苗（OHM/02株+AKT-Ш株）的新兽药证书，预计将在年内获得生产批件口蹄疫疫苗作为畜用疫苗中份额最大的单品，市场前景广阔，本次与礼蓝动保合作是结合双方优势的一次“双赢”，双方都将致力于为中国的口蹄疫疫病预防做出积极贡献。

关于海利生物

上海海利生物技术股份有限公司(SH:603718)是一家集研发、生产、销售、服务于一体的专业化兽用生物制品生产企业。公司是农业部在上海批准生产兽用生物制品的定点企业及农业部在上海设立的动物重大疫情防治生产基地，产品线齐全，产品结构完善，具备全方位服务的产品基础和能力。与此同时，公司积极开展对外投资，积极落实“动保+人保”的双轮驱动布局：2018年全资收购了从事医用体外诊断试剂研究、开发、和生产的高新技术企业上海捷门生物技术有限公司；与药明生物合资设立了主要从事人用疫苗（包括癌症疫苗）的CDMO业务的上海药明海德生物科技有限公司，构建全生物产业链的布局，在更广阔的平台上实现转型升级。

关于杨凌金海

杨凌金海生物技术有限公司是海利生物与全球最大的口蹄疫疫苗生产商之一的阿根廷BiogénesisBagóS.A.公司共同合资兴建、国内唯一的一家中外合资的口蹄疫疫苗生产企业。杨凌金海采用BB 公司最先进和最稳定的全悬浮、高纯化生产工艺技术进行口蹄疫疫苗的生产，其工艺规模化技术水平位居全球行业前列，致力于为中国的口蹄疫疫病预防做出积极贡献。

关于礼蓝动保

礼蓝动保(NYSE:ELAN）是一家国际化的动保公司，业务遍布超过90个国家，公司致力于不断研发并生产高品质的产品并为客户提供优质的服务，以改善食品动物和伴侣动物的健康。传承于64年的积淀，我们戮力创新，惠及客户。同时，我们在全球拥有超过5,800名员工，我们始终秉持包容和进取的企业文化。作为礼蓝人，我们心系使命—让食品和伴侣动物不断丰富我们的生活，使动物、人类和地球变得更健康！礼蓝动保从礼来公司（EliLilly and Company）剥离后，现已成为一家完全独立的上市公司。 Elanco的中文名称现已变更为“礼蓝（上海）动物保健有限公司”。更多信息，请查询www.elanco.com。

Yangling Jinhai Biotechnology Co., Ltd., the majority owned subsidiary of Shanghai Hile Bio-Technology Co.,Ltd. entered into an exclusive promotion agreement with Elanco (Shanghai) Animal Health Co., Ltd.

On August 20th, 2019, Yangling Jinhai Biotechnology Co., Ltd. (“YanglingJinhai”), the majority owned subsidiary of Shanghai Hile Bio-Technology Co.,Ltd. (SH:603718) entered into an exclusive promotion agreement with Elanco (Shanghai) Animal Health Co., Ltd.(“Elanco China”), the subsidiary of Elanco US Inc. Yangling Jinhai has appointed Elanco China to exclusively promote its foot-and-mouth disease(FMD) vaccine in China (including the Hong Kong Special Administrative Region and the Macau Special Administrative Region) via private market promotion channels. Elanco China will make best use of its resources and advantages to assist in the promotion of the product of Yangling Jinhai.

The exclusive promotion agreement executed between Yangling Jinhai and Elanco China is an important step of Hile-Bio’s internationalization. Yangling Jinhai is a joint venture established by Hile-Bio and BiogénesisBagó S.A., and it is the only joint venture which produces FMD vaccine in China. On January 22, 2019,Yangling Jinhai obtained the new veterinary drug certificate for swine type O and A bivalent inactivated vaccine (OHM/02+AKT-Ш), and it is expected to obtain the manufacturing permit by the end of this year. FMD vaccine is the largest vaccine category in animal health sector with promising growth in the future. The cooperation with Elanco China is a win-win cooperation, with the advantages of both parties combined. The parties will use their best endeavors to contribute to the prevention of FMD disease in China.

About Hile

ShanghaiHile Bio-Technology Co.,Ltd. (SH:603718) is an integrated veterinary biological product company of product research and development, manufacturing, selling and technical services. Hile-Bio is the appointed enterprise of the Ministry of Agriculture to produce veterinary biological products in Shanghai. It is also the appointed manufacturing base to prevent and control major animal outbreaks. Hile-Bio has a full range of product portfolio and sound product mix, with strong capabilities of providing full services. Meanwhile, Hile-Bio is active in investment and is executing “Animal Health + Human Health” strategy. In 2018, Hile-Bio acquired JieMen Bio-Technology Co.,Ltd. which is a high-tech enterprise specializing in the product research, development, and manufacturing of medical in-vitro diagnostic reagents. Hile-Bio also established a joint venture with Wuxi Biologics specializing in CDMO business of human vaccine (including cancer vaccine). Hile-Bio is targeting at the whole biologic chain and making efforts to achieve transformation via a broader platform.

About Yangling JinHai

Yangling Jinhai Biotechnology Co., Ltd. is the joint venture of Hile-Bio with BiogénesisBagóS.A. from Argentina, one of the worldwide biggest FMD vaccine manufacturing companies. Yangling Jinhai is the only sino-foreign joint venture manufacturing FMD vaccine products in China. It adopts the most advanced and high stability level of full suspension and high purity production technologies. YanglingJinHai's production capacity and technologies both rank in the top of the industry globally and it is dedicated to FMD prevention and control.

About Elanco

Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, werigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life — all to advance the health of animals, people and the planet. Learn more at www.elanco.com